# A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

> **NCT01578707** · PHASE3 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 391 (actual)

## Conditions studied

- Relapsed or Refractory Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** ofatumumab
- **DRUG:** ibrutinib

## Key facts

- **NCT ID:** NCT01578707
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2013-11
- **Final completion:** 2018-10-25
- **Target enrollment:** 391 (ACTUAL)
- **Last updated:** 2019-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01578707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01578707, "A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01578707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*